May 28, 2025
A New Dawn for Psychedelics: Compass Pathways Nears Major Phase 3 Psilocybin Results
Compass Pathways; COMP360; psilocybin; treatment-resistant depression; phase 3 trial; psychedelic therapy; FDA Breakthrough Therapy; mental health innovation
GSK, Spero Report Major Phase 3 Win for UTI Antibiotic; Spero’s Stock Surges
GSK; Spero Therapeutics; tebipenem HBr; Phase 3 trial; UTI antibiotic; complicated urinary tract infection; PIVOT-PO trial; stock surge; clinical trial results; FDA submission
Uncertainty Surrounds Moderna’s Next-Generation COVID Shot Amid Policy Changes
Moderna; COVID-19 vaccine; FDA policy; combination flu/COVID-19 shot; vaccine access; mRNA-1083; vaccine recommendations; regulatory setback
RFK Jr. Ends CDC Covid Vaccine Recommendations for Healthy Children and Pregnant Women
RFK Jr.; COVID-19 vaccine; recommendations; children; pregnant women; CDC; HHS Secretary; public health policy
Recent Developments in NLP and Generative AI for Life Sciences and Precision Medicine (2025)
NLP; Generative AI; life sciences; precision medicine; healthcare; large language models; multimodal AI; quality management; drug discovery; pharmacovigilance
InflaRx Halts Rare Skin Disease Study for Vilobelimab After Futility Signal
InflaRx; vilobelimab; pyoderma gangrenosum; futility; clinical trial; COVID-19; drug development; INF904
Fierce Biotech Fundraising Tracker ’25: Grin Raises $140M Series D and Strikes Major Angelini Deal; Syndeio Secures $90M
Grin Therapeutics; Series D financing; radiprodil; Angelini Pharma; Blackstone Life Sciences; Syndeio; biotech fundraising; neurodevelopmental disorders; pharma partnerships
Eli Lilly Acquires SiteOne for Up to $1B to Expand Non-Opioid Pain Pipeline
Eli Lilly; SiteOne Therapeutics; non-opioid pain treatment; STC-004; acquisition; Nav1.8 inhibitor; chronic pain; neuroscience pipeline; Vertex; pharmaceutical industry